GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neumora Therapeutics Inc (NAS:NMRA) » Definitions » Dividend Yield %

NMRA (Neumora Therapeutics) Dividend Yield % : 0.00% (As of Dec. 13, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neumora Therapeutics Dividend Yield %?

As of today (2024-12-13), the Trailing Annual Dividend Yield of Neumora Therapeutics is 0.00%.

The historical rank and industry rank for Neumora Therapeutics's Dividend Yield % or its related term are showing as below:

NMRA's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.42
* Ranked among companies with meaningful Dividend Yield % only.

Neumora Therapeutics's Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00.

As of today (2024-12-13), the Forward Dividend Yield % of Neumora Therapeutics is 0.00%.

Neumora Therapeutics's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Neumora Therapeutics Dividend Yield % Historical Data

The historical data trend for Neumora Therapeutics's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neumora Therapeutics Dividend Yield % Chart

Neumora Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Dividend Yield %
- - - - -

Neumora Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Dividend Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Neumora Therapeutics's Dividend Yield %

For the Biotechnology subindustry, Neumora Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neumora Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neumora Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Neumora Therapeutics's Dividend Yield % falls into.



Neumora Therapeutics Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Neumora Therapeutics  (NAS:NMRA) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Neumora Therapeutics Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Neumora Therapeutics's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Neumora Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
490 Arsenal Way, Suite 200, Watertown, MA, USA, 02472
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
Executives
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Robert A. Lenz officer: Head of R&D C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Joshua Pinto officer: Chief Financial Officer C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Kristina Burow director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Xii, Llc 10 percent owner 8755 W HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Henry O Gosebruch director, officer: President & CEO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Arch Venture Fund X, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Amgen Inc 10 percent owner ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Arch Venture Fund Xii, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Daljit Singh Aurora officer: Chief Strategy Officer C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Arch Venture Partners Viii, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Xii, L.p. 10 percent owner 8755 W HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631